Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending December 07, 2005. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding Ordinary Shares of the Company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a regulatory notification of share transactions and does not contain financial performance data.
Material Changes
The material change reported is a transfer of 101,400 Ordinary Shares from the GlaxoSmithKline Employee Trust ("the GSK Trust") to participants in the SmithKline Beecham Employee Share Option Plan 1991. This transaction occurred on December 5, 2005, and was advised to the Company on December 6, 2005.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The transaction is noted as being in accordance with Disclosure Rule 3.1.4R (1) (b). The GSK Trust is identified as a discretionary trust where all current and former employees are potential beneficiaries.
Investor Verification Points
- Verify the impact of the 101,400 share transfer on the total outstanding share count.
- Confirm the specific identities of the SmithKline Beecham Employee Share Option Plan 1991 participants receiving the shares.
- Review the full terms of the GSK Trust to understand the scope of employee benefits.
- Note that three directors (Dr J-P Garnier, Dr T Yamada, and Mr J S Heslop) hold interests in the GSK Trust shares similarly to other employees.